Abstract
Preferentially expressed antigen of melanoma (PRAME) has been described as a potential candidate for immunotherapeutic targeting. However, the prognostic and predictive relevance of PRAME in breast cancer has never been investigated. PRAME gene expression was evaluated in 103 breast tumour biopsies, using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Normal breast tissue was also analysed for comparative purposes. All qRT-PCRs were performed in triplicate. Kaplan–Meier survival curves, Chi-squared and Cox Regression analyses were used to identify associations between PRAME expression and patients’ clinicopathological and survival data. PRAME mRNA was detected in ∼53% of tumour specimens and 37% of normal breast specimens. Kaplan–Meier analysis showed expression of PRAME to correlate significantly with unfavourable disease outcome for patients, in terms of both their disease-free survival (p = 0.0004) and overall survival (OS) (p = 0.0052) times from diagnosis. Multivariate analysis indicated PRAME expression to be an independent prognostic factor for shortened disease-free survival (p = 0.026) and OS (p = 0.02). Furthermore, for patients who received adjuvant chemotherapy, significantly (p = 0.0291) shorter relapse-free survival was achieved for those whose tumour expressed PRAME, compared to those that did not express this transcript. Our results suggest that PRAME mRNA expression may be a useful prognostic and predictive marker for breast cancer.
Similar content being viewed by others
References
Ikeda H, Lethe B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208
Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R (2005) The human tumour antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835–847
Epping MT, Bernards R (2006) A causal role for the human tumour antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 66:10639–10642
Neumann E, Engelsberg A, Decker J et al (1998) Heterogeneous expression of the tumour-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 58:4090–4095
Li CM, Guo M, Borczuk A et al (2002) Gene expression in Wilms’ tumour mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160:2181–2190
Matsushita M, Yamazaki R, Kawakami Y (2004) Quantitative analysis of PRAME for detection of minimal residual disease in leukaemia. Methods Mol Med 97:267–275
Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M (2004) The tumour-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10:4307–4313
Proto-Siqueira R, Figueiredo-Pontes LL, Panepucci RA et al (2006) PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 30:1333–1339
Page DL, Andersen AT (1987) Diagnostic histopathology. Churchill Livingstone, London, Melbourne and New York
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 403–410
Sobin LH, Wittekind C (1997) TNM Classification of Malignant tumours. Wiley, New York
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T). Methods 25:402–408
van Baren N, Chambost H, Ferrant A et al (1998) PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 102:1376–1379
Watari K, Tojo A, Nagamura-Inoue T et al (2000) Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett 466:367–371
McElwaine S, Mulligan C, Groet J et al (2004) Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down’s syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol 125:729–742
Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R (2005) PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 79:257–261
Tajeddine N, Millard I, Gailly P, Gala JL (2006) Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med 44:548–555
Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B (2002) Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133:118–123
Steinbach D, Viehmann S, Zintl F, Gruhn B (2002) PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 138:89–91
van Baren N, Brasseur F, Godelaine D et al (1999) Genes encoding tumour-specific antigens are expressed in human myeloma cells. Blood 94:1156–1164
Matsushita M, Ikeda H, Kizaki M et al (2001) Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 112:916–926
Acknowledgements
This work was supported by funding from Ireland’s Higher Educational Authority Programme for Research in Third Level Institutions (PRTLI) Cycle 3, Dublin City University’s Albert College Fellowship, Dublin City University’s Research Fellowship and the Health Research Board.
Author information
Authors and Affiliations
Corresponding author
Additional information
Padraig Doolan and Martin Clynes contributed equally to this work.
Rights and permissions
About this article
Cite this article
Doolan, P., Clynes, M., Kennedy, S. et al. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat 109, 359–365 (2008). https://doi.org/10.1007/s10549-007-9643-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9643-3